WuXi STA gets FDA nod for new facility

Chinese pharma development firm WuXi STA has announced that its newly-built facility in Changzhou has received perfect feedback from the US Food and Drug Administration (FDA) in its inaugural inspection.

The company claims to have passed with a faultless record, receiving no observations in its bid for approval. Its success means that WuXi can begin to work on developing two active pharmaceutical ingredients (APIs) for the US market.

WuXi chief executive Minzhang Chen said: "The Changzhou facility passing its first FDA inspection, with no observations – or even written or verbal recommendations – is yet further proof of our commitment to the highest possible quality standards. It’s a point of great pride that we have an exemplary regulatory record, and evidence of the company’s ability to supply the US market with innovative commercial APIs from the Changzhou site.”